Jane Wolstenholme

5.0k total citations
107 papers, 3.5k citations indexed

About

Jane Wolstenholme is a scholar working on Economics and Econometrics, Oncology and General Health Professions. According to data from OpenAlex, Jane Wolstenholme has authored 107 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Economics and Econometrics, 23 papers in Oncology and 19 papers in General Health Professions. Recurrent topics in Jane Wolstenholme's work include Health Systems, Economic Evaluations, Quality of Life (32 papers), Healthcare Policy and Management (15 papers) and Prenatal Screening and Diagnostics (14 papers). Jane Wolstenholme is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (32 papers), Healthcare Policy and Management (15 papers) and Prenatal Screening and Diagnostics (14 papers). Jane Wolstenholme collaborates with scholars based in United Kingdom, United States and Netherlands. Jane Wolstenholme's co-authors include Alastair Gray, David K. Whynes, Emma Frew, Philip Clarke, Sarah Wordsworth, Oliver Rivero‐Arias, Andrew Briggs, Taane G. Clark, D K Whynes and R.R. Angell and has published in prestigious journals such as Nature, The Lancet and JAMA.

In The Last Decade

Jane Wolstenholme

104 papers receiving 3.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jane Wolstenholme United Kingdom 33 897 564 535 492 445 107 3.5k
Nicole F. Dowling United States 34 371 0.4× 459 0.8× 537 1.0× 547 1.1× 532 1.2× 87 5.8k
Erwin Birnie Netherlands 41 414 0.5× 1.1k 1.9× 577 1.1× 521 1.1× 375 0.8× 233 5.4k
William Lawrence United States 29 1.1k 1.3× 335 0.6× 932 1.7× 392 0.8× 669 1.5× 70 3.8k
Christopher Hyde United Kingdom 39 497 0.6× 304 0.5× 382 0.7× 658 1.3× 631 1.4× 115 5.6k
Jason Madan United Kingdom 26 582 0.6× 418 0.7× 471 0.9× 257 0.5× 515 1.2× 133 2.9k
Jinoos Yazdany United States 47 419 0.5× 221 0.4× 614 1.1× 431 0.9× 729 1.6× 251 8.1k
Neil Hawkins United Kingdom 33 1.1k 1.2× 394 0.7× 355 0.7× 159 0.3× 651 1.5× 150 5.5k
J. Chilcott United Kingdom 39 1.2k 1.3× 267 0.5× 611 1.1× 177 0.4× 410 0.9× 145 4.4k
Tom Marshall United Kingdom 42 1.1k 1.3× 434 0.8× 1.1k 2.1× 357 0.7× 1.1k 2.5× 250 7.3k
Allan Wailoo United Kingdom 40 1.7k 1.9× 384 0.7× 776 1.5× 147 0.3× 537 1.2× 123 4.6k

Countries citing papers authored by Jane Wolstenholme

Since Specialization
Citations

This map shows the geographic impact of Jane Wolstenholme's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Wolstenholme with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Wolstenholme more than expected).

Fields of papers citing papers by Jane Wolstenholme

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Wolstenholme. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Wolstenholme. The network helps show where Jane Wolstenholme may publish in the future.

Co-authorship network of co-authors of Jane Wolstenholme

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Wolstenholme. A scholar is included among the top collaborators of Jane Wolstenholme based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Wolstenholme. Jane Wolstenholme is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hobbs, Richard, Richard J. McManus, Clare Taylor, et al.. (2025). Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT. Health Technology Assessment. 29(5). 1–130. 1 indexed citations
2.
Hobbs, Richard, Richard J. McManus, Clare Taylor, et al.. (2024). Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial. Nature Medicine. 30(12). 3634–3645. 16 indexed citations
3.
Jones, David A., Katie Spencer, Laurence Roope, et al.. (2024). Inequalities in geographic barriers and patient representation in lymphoma clinical trials across England. British Journal of Haematology. 206(2). 531–540. 2 indexed citations
4.
Ordóñez-Mena, José M, Yaling Yang, Jane Wolstenholme, et al.. (2022). Quality of life in older adults with chronic kidney disease and transient changes in renal function: Findings from the Oxford Renal cohort. PLoS ONE. 17(10). e0275572–e0275572. 2 indexed citations
5.
6.
Wolstenholme, Jane, et al.. (2022). Estimating BMI distributions by age and sex for local authorities in England: a small area estimation study. BMJ Open. 12(6). e060892–e060892. 5 indexed citations
7.
Burns, Richéal, Jane Wolstenholme, Sena Jawad, et al.. (2018). Economic analysis of oral dexamethasone for symptom relief of sore throat: the UK TOAST study. BMJ Open. 8(4). e019184–e019184. 7 indexed citations
8.
Landeiro, Filipa, Katie Walsh, Isaac Ghinai, et al.. (2018). Measuring quality of life of people with predementia and dementia and their caregivers: a systematic review protocol. BMJ Open. 8(3). e019082–e019082. 15 indexed citations
9.
Wang, Kay, Sharon Tonner, Malcolm G. Semple, et al.. (2018). Early use of Antibiotics for at Risk CHildren with InfluEnza (ARCHIE): protocol for a double-blind, randomised, placebo-controlled trial. BMJ Open. 8(5). e021144–e021144. 3 indexed citations
10.
11.
Dunwoodie, Elaine, Richard Jones, Alex Newsham, et al.. (2017). Process mining routinely collected electronic health records to define real-life clinical pathways during chemotherapy. International Journal of Medical Informatics. 103. 32–41. 62 indexed citations
12.
Burns, Richéal, José Leal, Jane Wolstenholme, et al.. (2016). The Burden of Healthcare Costs Associated with Prostate Cancer in Ireland. Global & Regional Health Technology Assessment. 4(1). 28–33.
13.
Hill, Nathan R., Daniel Lasserson, Samuel Fatoba, et al.. (2013). The Oxford Renal (OxRen) cross-sectional study of chronic kidney disease in the UK. BMJ Open. 3(12). e004265–e004265. 5 indexed citations
14.
Gray, Alastair, Philip Clarke, Jane Wolstenholme, & Sarah Wordsworth. (2010). Applied Methods of Cost-effectiveness Analysis in Healthcare. RePEc: Research Papers in Economics. 280 indexed citations
15.
Briggs, Andrew, Borislava Mihaylova, Mark Sculpher, et al.. (2006). Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart. 93(9). 1081–1086. 48 indexed citations
16.
Frew, Emma, Jane Wolstenholme, & David K. Whynes. (2001). Willingness-to-pay for colorectal cancer screening. European Journal of Cancer. 37(14). 1746–1751. 66 indexed citations
17.
Frew, Emma, Jane Wolstenholme, & David K. Whynes. (2001). Mass population screening for colorectal cancer: factors influencing subjects' choice of screening test. Journal of Health Services Research & Policy. 6(2). 85–91. 29 indexed citations
18.
Torgerson, David, et al.. (1999). Costs of breast cancer treatment in the United Kingdom. The Breast. 8(4). 205–207. 7 indexed citations
19.
Muir, K. R., et al.. (1997). Continued inadequacies in data sources for the evaluation of cancer services. British Journal of Cancer. 75(1). 131–133. 6 indexed citations
20.
Webb, Alison L., Stephen N. Sturgiss, Paul Warwicker, et al.. (1996). MATERNAL UNIPARENTAL DISOMY FOR CHROMOSOME 2 IN ASSOCIATION WITH CONFINED PLACENTAL MOSAICISM FOR TRISOMY 2 AND SEVERE INTRAUTERINE GROWTH RETARDATION. Prenatal Diagnosis. 16(10). 958–962. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicole F. Dowling Breakdown of academic impact, for papers by Erwin Birnie Breakdown of academic impact, for papers by William Lawrence Breakdown of academic impact, for papers by Christopher Hyde Breakdown of academic impact, for papers by Jason Madan Breakdown of academic impact, for papers by Jinoos Yazdany Breakdown of academic impact, for papers by Neil Hawkins Breakdown of academic impact, for papers by J. Chilcott Breakdown of academic impact, for papers by Tom Marshall Breakdown of academic impact, for papers by Allan Wailoo
Rankless by CCL
2026